The license agreement with the NRC grants Appili exclusive worldwide rights to develop and commercialize this tularemia vaccine.
ATI-1701 is based on research led by Dr. Wayne Conlan at the NRC. Conlan's team used genetic engineering to disable a previously virulent strain of F. tularensis and develop a live attenuated vaccine. Their research showed the genetically modified bacterium induced a strong immune response that triggers a protective immune response to F. tularensis.
Some of the development work for the vaccine is being funded by the Defense Threat Reduction Agency, part of the US Department of Defense, which recently announced a USD6.2 m, 5-year program to develop a tularemia vaccine.
Appili will conduct the preclinical and clinical testing required by the FDA to evaluate the safety of the ATI-1701 vaccine and to ensure it offers the desired protection against the bacteria for humans.
Appili is dedicated to identifying, acquiring, and advancing novel therapeutics for infectious disease.
Its pipeline includes three anti-infective programs: ATI-1501, a novel taste-masking technology applied in an oral suspension for the treatment for anaerobic infections, ATI-1503, a novel antibiotic targeting drug-resistant Gram-negative infections, and ATI-1701, a vaccine reducing the threat of tularemia bioterrorism.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer